Clinical Trial

For Knee Pain the Care You Get Depends on Where You Live, New Report Finds

New data from Motive Medical Intelligence shows that many patients with knee arthritis fail to receive the basic care recommended…

2 weeks ago

Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials

BOSTON, Dec. 11, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science…

2 weeks ago

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and…

2 weeks ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™Financing led by…

2 weeks ago

Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)

Thomas Smeenk, BA, unveils a proposed conformal invariant, A = E/(hv), explored as a potential bridge between General Relativity, Quantum…

2 weeks ago

Hemostemix Grants Stock Options

Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

2 weeks ago

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA /…

2 weeks ago

Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv

The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated…

2 weeks ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent,…

2 weeks ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership,…

2 weeks ago